Sone-296

| Parameter | Details | |-----------|---------| | | Open‑label, dose‑escalation (3 + 3), followed by expansion cohorts. | | Population | Adults with advanced solid tumors refractory to standard therapy. | | Dose range | 5 mg – 200 mg QD oral. | | Primary endpoints | Safety/tolerability, MTD, pharmacokinetics. | | Key secondary endpoints | Preliminary efficacy (RECIST response), pharmacodynamics (target inhibition in tumor biopsies). | | Status | Completed (2024); MTD = 150 mg QD, RP2D = 120 mg QD. |

The enigma of SONE-296 continues to fascinate and intrigue online communities. While we've explored various theories and speculations, the true meaning and significance of this term remain shrouded in mystery. As researchers and enthusiasts, we must continue to investigate and gather information, hoping to uncover the secrets hidden behind this cryptic code. SONE-296

A brief, one‑paragraph summary that states: | Parameter | Details | |-----------|---------| | |

Based on available records, "SONE-296" appears most frequently in two very different contexts. It is likely that you are referring to one of the following: 1. Adult Entertainment Industry (JAV) In most digital search contexts, | The enigma of SONE-296 continues to fascinate